Please assess the completion status of the following clinical trial:

Trial Title: The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia by two senior psychiatrists~* Between 18 and 60 years and Han Chinese~Exclusion Criteria:~* A Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV Axis I diagnosis other than schizophrenia~* Documented disease of physical diseases including, but not limited to seizure, epilepsy, aneurysm brain tumor, and stroke, dementia, parkinson's disease, Huntington's disease, multiple sclerosis~* Acute, unstable and/or significant and untreated medical illness (e.g., infection, unstable diabetes, uncontrolled hypertension)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- olanzapine-sertraline combination (Type: EXPERIMENTAL): the patient was prescribed low-dose olanzapine (7.5-10mg/day) combined with low-dose sertraline (50-100mg/day)
- only olanzapine (Type: PLACEBO_COMPARATOR): the patient was prescribed moderate to severity dose of olanzapine (12.5-20mg/day)
- risperidone-sertraline combination (Type: EXPERIMENTAL): the patient was prescribed low-dose risperidone (2-3.5mg/day) combined with low-dose sertraline (50-100mg/day)
- only risperidone (Type: PLACEBO_COMPARATOR): the patient was prescribed moderate to severity dose of risperidone (4-6mg/day)
- paliperidone-sertraline combination (Type: EXPERIMENTAL): the patient was prescribed low-dose paliperidone (3-4.5mg/day) combined with low-dose sertraline (50-100mg/day)
- only paliperidone (Type: PLACEBO_COMPARATOR): the patient was prescribed moderate to severity dose of paliperidone (6-9mg/day)
- ziprasidone-sertraline combination (Type: EXPERIMENTAL): the patient was prescribed low-dose ziprasidone (60-100mg/day) combined with low-dose sertraline (50-100mg/day)
- only ziprasidone (Type: PLACEBO_COMPARATOR): the patient was prescribed moderate to severity dose of ziprasidone (120-160mg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).